Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or for treating patients with hyperphosphatemia.
1. A lanthanum dioxycarbonate having at least one of 0.75% by weight or less of sodium, or a pore volume of at least 0.015 cm 3 /g, and has particles having spherical morphology.
2. The lanthanum dioxycarbonate of claim 1 , wherein the lanthanum dioxycarbonate has 0.75% by weight or less of sodium, and a pore volume of at least 0.015 cm 3 /g.
3. The lanthanum dioxycarbonate of claim 1 , wherein the lanthanum dioxycarbonate has the pore volume of at least 0.015 cm 3 /g.
4. The lanthanum dioxycarbonate of claim 1 , wherein the lanthanum dioxycarbonate has 0.75% by weight or less of sodium.
5. A pharmaceutical composition comprising an effective amount of the lanthanum dioxycarbonate of claim 1 , and at least one pharmaceutically acceptable excipient.
6. The pharmaceutical composition of claim 5 , wherein said pharmaceutical composition is swallow tablets, swallow caplets, compressed dosage forms, swallow hard gelatin capsules, swallow soft gel capsules, orally dissolvable tablets, orally dissolvable caplets, orally dissolvable hard gelatin capsules, orally dissolvable soft gelatin capsules, chewable tablets, chewable caplets, chewable capsules, powders, sprinkles, orally disintegrable films, foods, confections, gums, syrups, suspensions, emulsions or dispersions.
7. The pharmaceutical composition of claim 5 , wherein an amount of lanthanum dioxycarbonate ranges from between about 125 mg to about 20,000 mg and wherein said lanthanum dioxycarbonate has a formula La 2 O 2 CO 3 .
8. The pharmaceutical composition of claim 5 , wherein an amount of the lanthanum dioxycarbonate is selected from the group consisting of from about 100, 125, 150, 250, 500, 750, or 1000 mg.
9. The pharmaceutical composition of claim 5 , wherein the lanthanum dioxycarbonate having 0.75% by weight or less of sodium.
10. The pharmaceutical composition of claim 5 , where the lanthanum dioxycarbonate having the pore volume of at least 0.015 cm 3 /g.
11. A method for the treatment of a condition characterized by an abnormally elevated level of phosphate in the blood, wherein the method comprises:
administering to a subject in need thereof an effective amount of a pharmaceutical composition, the pharmaceutical composition comprising:
an effective amount of the lanthanum dioxycarbonate of claim 1 , and at least one pharmaceutically acceptable excipient.
12. The pharmaceutical composition of claim 11 , wherein the condition is selected from the group consisting of hyperphosphatemia, chronic kidney disease, general kidney failure, end stage renal disease, and chronic renal insufficiency.
13. The pharmaceutical composition of claim 11 , wherein said pharmaceutical composition is swallow tablets, swallow caplets, compressed dosage forms, swallow hard gelatin capsules, swallow soft gel capsules, orally dissolvable tablets, orally dissolvable caplets, orally dissolvable hard gelatin capsules, orally dissolvable soft gelatin capsules, chewable tablets, chewable caplets, chewable capsules, powders, sprinkles, orally disintegrable films, foods, confections, gums, syrups, suspensions, emulsions or dispersions.
14. The pharmaceutical composition of claim 11 , wherein an amount of lanthanum dioxycarbonate ranges from between about 125 mg to about 20,000 mg and wherein said lanthanum dioxycarbonate has a formula La 2 O 2 CO 3 .
15. The pharmaceutical composition of claim 11 , wherein an amount of the lanthanum dioxycarbonate is selected from the group consisting of from about 100, 125, 150, 250, 500, 750, or 1000 mg.
16. The pharmaceutical composition of claim 11 , wherein the lanthanum dioxycarbonate having 0.75% by weight or less of sodium.
17. The pharmaceutical composition of claim 11 , where the lanthanum dioxycarbonate having the pore volume of at least 0.015 cm 3 /g.